Centogene N.V. (CNTG)

$1.5

+0.03 (+2.04%)
Rating:
Recommendation:
-
Symbol CNTG
Price $1.5
Beta -1.182
Volume Avg. 0.01M
Market Cap 40.622M
Shares () -
52 Week Range 1.34-11.55
1y Target Est -
DCF Unlevered CNTG DCF ->
DCF Levered CNTG LDCF ->
ROE -125.82% Strong Sell
ROA -44.81% Strong Sell
Operating Margin -
Debt / Equity 231.07% Strong Buy
P/E -
P/B 0.91 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CNTG news


Prof. Arndt Rolfs
Healthcare
Diagnostics & Research
NASDAQ Global Market

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.